Noxafil (Posaconazole Oral Suspension) Drug Information: Overdosage and Contraindications

Pill Identifier Search

May 27, 2012

Noxafil

Yeast Infection »

What is yeast?

Yeast is a fungus scientifically referred to as Candida. The specific type of fungus most commonly responsible for vaginitis is Candida albicans. Yeast is commonly present on normal human skin and in areas of moisture, such as the mouth and vagina. In fact, it is estimated that between 20%-50% of healthy women normally carry yeast in the vaginal area.

What is vaginitis?

Vaginitis is inflammation of the vagina. Vaginitis is very common and is reported by as many as 75% of women at some point in their lives. Vaginitis can be caused by a number of infections, including bacteria (such as Gardnerella and gonorrhea), protozoans (such as trichomonas), and yeast (Candida). Vaginal yeast infection, which is the most common form of vaginitis, is often referred to as vaginal Candidiasis.

What is vulvitis?

Vulvitis is inflammation of the external ...

Read the Yeast Infection article »

« Previous
1
2
3
4
5
6
7
8
9
10
11
12
13
Next »

Noxafil User Reviews >>

Noxafil

Adult Skin Problems Slideshow Pictures

Quiz: Can You Identify These Skin Conditions?

Gallery of Skin Problems and Image Collection

font size

OVERDOSE

During the clinical trials, some patients received posaconazole up to 1600 mg/day with no adverse reactions noted that were different from the lower doses. In addition, accidental overdose was noted in one patient who took 1200 mg BID for 3 days. No related adverse reactions were noted by the investigator.

Posaconazole is not removed by hemodialysis.

CONTRAINDICATIONS

Hypersensitivity

NOXAFIL is contraindicated in persons with known hypersensitivity to posaconazole, any component of NOXAFIL (posaconazole oral suspension) , or other azole antifungal agents.

Use With Sirolimus

NOXAFIL (posaconazole oral suspension) is contraindicated with sirolimus. Concomitant administration of NOXAFIL (posaconazole oral suspension) with sirolimus increases the sirolimus blood concentrations by approximately 9 fold and can result in sirolimus toxicity [see DRUG INTERACTIONSand CLINICAL PHARMACOLOGY].

QT Prolongation With Concomitant Use With CYP3A4 Substrates

NOXAFIL (posaconazole oral suspension) is contraindicated with CYP3A4 substrates that prolong the QT interval. Concomitant administration of NOXAFIL (posaconazole oral suspension) with the CYP3A4 substrates, pimozide and quinidine may result in increased plasma concentrations of these drugs, leading to QTc prolongation and rare occurrences of torsades de pointes [see WARNINGS AND PRECAUTIONSand DRUG INTERACTIONS].

Use With Simvastatin

Concomitant administration of NOXAFIL (posaconazole oral suspension) with simvastatin increases the simvastatin plasma concentrations by approximately 10 fold. Increased plasma statin concentrations can be associated with rhabdomyolysis [see DRUG INTERACTIONS and CLINICAL PHARMACOLOGY].

Use With Ergot Alkaloids

Posaconazole may increase the plasma concentrations of ergot alkaloids (ergotamine and dihydroergotamine) which may lead to ergotism [see DRUG INTERACTIONS].

Last reviewed on RxList: 10/12/2010
This monograph has been modified to include the generic and brand name in many instances.